^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ARHGAP42 (Rho GTPase Activating Protein 42)

    i
    Other names: ARHGAP42, Rho GTPase Activating Protein 42, GRAF3, TMEM133, AD031, Rho-Type GTPase-Activating Protein 42, Rho GTPase-Activating Protein 42, Transmembrane Protein 133, FLJ32810, Rho GTPase-Activating Protein 10-Like
    Associations

    News

    Trials
    10ms
    The gene-panel obtained by anti-PD-1 monotherapy for melanoma reveals prognostic markers and therapeutic targets. (PubMed, J Chemother)
    Chemotherapy drug response models found five potential drugs, including all-trans retinoic acid, doxorubicin, etoposide, methotrexate and MG-132, were significantly associated with target genes in gene-panel. Molecular docking confirmed that potential drugs have good binding ability to target genes APP, GSTA4 and UCHL1, suggesting that the multi-gene panel is expected to provide assistance for drug resistance prediction and prognosis assessment and combination therapy in patients with anti-PD-1 resistant melanoma.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    ARHGAP42 (Rho GTPase Activating Protein 42)
    |
    doxorubicin hydrochloride • etoposide IV • methotrexate • MG132
    1year
    Detection of Novel Fusion Events in Gastric Carcinoma Involving the ARHGAP Gene Family (AMP 2024)
    Our study documents novel fusions in MSS gastric carcinoma involving the ARHGAP family. Patients with these tumors usually lack eligibility for targeted therapies, such as those directed against HER2 and involving immune checkpoint inhibition, and could ultimately benefit from new treatment avenues modulating RHOA activity as a result of ARHGAP fusions.
    Tumor mutational burden • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • ARID1A (AT-rich interaction domain 1A) • CLDN18 (Claudin 18) • PBRM1 (Polybromo 1) • KMT2D (Lysine Methyltransferase 2D) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • KDM6A (Lysine Demethylase 6A) • RHOA (Ras homolog family member A) • SOX9 (SRY-Box Transcription Factor 9) • ELF3 (E74 Like ETS Transcription Factor 3) • ARHGAP • CDKN1B (Cyclin dependent kinase inhibitor 1B) • CTNND1 (Catenin Delta 1) • ARHGAP42 (Rho GTPase Activating Protein 42)
    |
    TMB-H • HER-2 amplification • PBRM1 mutation
    |
    MI Tumor Seek™
    over1year
    A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma. (PubMed, Front Immunol)
    Taking this into consideration, herein, we conducted a retrospective study in order to develop and validate a gene expression score for predicting clinical benefit to the anti-PD-1 antibody nivolumab in the context of patients diagnosed with advanced clear cell RCC enrolled in the CheckMate-009, CheckMate-010, and CheckMate-025 clinical trials...Lastly, we explored the correlation of our 3GES with different clinical, molecular, and immune tumor characteristics. If the results of this study are definitively validated in other retrospective and large-scale, prospective studies, the 3GES will represent a valuable tool for guiding the design of ICB-based clinical trials in the aRCC scenario in the near future.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    NUP62 (Nucleoporin 62) • ARHGAP42 (Rho GTPase Activating Protein 42)
    |
    Opdivo (nivolumab)
    3years
    Malignant Undifferentiated Epithelioid Neoplasms with MAML2 rearrangements: a Clinicopathologic Study of Six Cases Demonstrating a Heterogenous Entity. (PubMed, Genes Chromosomes Cancer)
    Of the 4 cases with detailed clinical history (median follow-up period 8 months), 3 developed distant metastatic disease (one of which died of disease); one case remained free of disease 3?years following surgical excision. In conclusion, we describe a heterogeneous series of MAML2-rearranged undifferentiated malignant epithelioid neoplasms, a small subset of which may overlap with a recently described MIFS variant with YAP1::MAML2 fusions, further expanding the clinicopathologic spectrum of mesenchymal neoplasms with recurrent MAML2 gene rearrangements.
    Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CCNE1 (Cyclin E1) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • YAP1 (Yes associated protein 1) • RBMS3 (RNA Binding Motif Single Stranded Interacting Protein 3) • ARHGAP42 (Rho GTPase Activating Protein 42) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
    |
    TP53 mutation • PTEN mutation • CDKN2A deletion • CCNE1 amplification • RB1 mutation • CCNE1 mutation • PDGFRB mutation